Opioid substitution therapy: Lowering the treatment thresholds

Drug and Alcohol Dependence

Volumn 161, Issue , 2016, Pages 1-8

  Kourounis, Georgios ^a,b   Richards, Brian David Wensley ^a,b   Kyprianou, Evdokia ^c   Symeonidou, Eva ^c   Malliori, Minerva Melpomeni ^d   Samartzis, Lampros ^a,b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b Athalassa Psychiatric Hospital   (Cyprus)

^c Cyprus Anti Drugs Council   (Cyprus)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Addiction; Buprenorphine; Cyprus; Drugs; Harm reduction; Heroin; Methadone; Opioid; OST; Policy; Substitution; Threshold

Indexed keywords

BUPRENORPHINE; METHADONE; OPIATE; NARCOTIC AGENT;

ARTICLE; CLINICAL ASSESSMENT; GROUP THERAPY; HEALTH CARE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HUMAN; META ANALYSIS; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PRESCRIPTION; PRIORITY JOURNAL; SYSTEMATIC REVIEW; THRESHOLD TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; HOSPITAL ADMISSION; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; PROCEDURES;

BUPRENORPHINE; HEALTH SERVICES ACCESSIBILITY; HUMANS; METHADONE; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; WAITING LISTS;

EID: 84962074485     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.12.021     Document Type: Review

References (84)

1. Adamson S.J., Sellman J.D. The pattern of intravenous drug use and associated criminal activity in patients on a methadone treatment waiting list. Drug Alcohol Rev 1998, 17:159-166. 10.1080/09595239800186961.
2. ACMD, Advisory Council on the Misuse of Drugs, Featherstone, L., 2014. Time-Limiting Opioid Substitution Therapy. Featherstone, I. (Ed.). Home Office London.
3. Amato L., Davoli M., Minozzi S., Vecchi S., Perucci C.A. Should psychosocial intervention be added to pharmacological treatment for opiate abuse/dependence? An overview of systematic reviews of the literature. Ital. J. Public Health 2012, 3:15-20. 10.2427/5931.
4. Amato L., Davoli M., Perucci C.A., Ferri M., Faggiano F., Mattick R.P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J. Subst. Abuse Treat 2005, 28:321-329. 10.1016/j.jsat.2005.02.007.
5. Amato L., Minozzi S., Davoli M., Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst. Rev. 2011, CD004147. 10.1002/14651858.cd004147.pub4.
6. Amato L., Minozzi S., Davoli M., Vecchi S., Ferri M.M.F., Mayet S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst. Rev. 2008, CD004147. 10.1002/14651858.cd004147.pub3.
7. Bach P., Milloy M.-J., Nguyen P., Koehn J., Guillemi S., Kerr T., Wood E. Gender differences in access to methadone maintenance therapy in a Canadian setting. Drug Alcohol Rev. 2015, epub ahead of print. 10.1111/dar.12251.
8. Bachireddy C., Bazazi A.R., Kavasery R., Govindasamy S., Kamarulzaman A., Altice F.L. Attitudes toward opioid substitution therapy and pre-incarceration HIV transmission behaviors among HIV-infected prisoners in Malaysia: implications for secondary prevention. Drug Alcohol Depend. 2011, 116:151-157. 10.1016/j.drugalcdep.2010.12.001.
9. Bao Y.-P., Liu Z.-M., Epstein D.H., Du C., Shi J., Lu L. A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am. J. Drug Alcohol Abuse 2009, 35:28-33. 10.1080/00952990802342899.
10. Bell J., Dru A., Fischer B., Levit S., Sarfraz M.A. Substitution therapy for heroin addiction. Subst. Use Misuse 2002, 37:1149-1178.
11. Blanken P., Hendriks V.M., Van Ree J.M., Van Den Brink W. Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands. Addiction 2010, 105:300-308. 10.1111/j.1360-0443.2009.02754.x.
12. Blanken P., van den Brink W., Hendriks V.M., Huijsman I.A., Klous M.G., Rook E.J., Wakelin J.S., Barendrecht C., Beijnen J.H., van Ree J.M. Heroin-assisted treatment in the Netherlands: history, findings, and international context. Eur. Neuropsychopharmacol. 2010, 20:S105-S158. 10.1016/s0924-977x(10) 70001-8.
13. Booth R.E., Corsi K.F., Mikulich-Gilbertson S.K. Factors associated with methadone maintenance treatment retention among street-recruited injection drug users. Drug Alcohol Depend. 2004, 74:177-185. 10.1016/j.drugalcdep.2003.12.009.
14. Bretteville-Jensen A.L., Lillehagen M., Gjersing L., Andreas J.B. Illicit use of opioid substitution drugs: prevalence, user characteristics, and the association with non-fatal overdoses. Drug Alcohol Depend. 2015, 147:89-96. 10.1016/j.drugalcdep.2014.12.002.
15. Chang K.-C., Lu T.-H., Lee K.-Y., Hwang J.-S., Cheng C.-M., Wang J.-D. Estimation of life expectancy and the expected years of life lost among heroin users in the era of opioid substitution treatment (OST) in Taiwanmation of life expectancy and the expected years of life lost among heroin users in the era of opioid substitution treatment (OST) in Taiwan. Drug Alcohol Depend. 2015, 153:152-158. 10.1016/j.drugalcdep.2015.05.033.
16. Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor R.J., Fry-Smith A., Day E., Lintzeris N., Roberts T., Burls A., Taylor R.S. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol. Assess. 2007, 11:1-171. iii-iv.
17. Coppel A. Good practice, good results: maintenance treatment outcomes in France.Heroin Addict. Relat. Clin. Probl. 2005, 7:19-24.
18. Coppel M.A. Opioid replacement therapy. Alcoologie et Addictologie 2005, 27:57S-67S.
19. Davstad I., Stenbacka M., Leifman A., Romelsj A. An 18-year follow-up of patients admitted to methadone treatment for the first time. J. Addict. Dis. 2009, 28:39-52. 10.1080/10550880802544997.
20. De Maeyer J., Vanderplasschen W., Broekaert E. Quality of life among opiate-dependent individuals: a review of the literature. Int. J. Drug Policy 2010, 21:364-380. 10.1016/j.drugpo.2010.01.010.
21. Deering D.E.A., Sheridan J., Sellman J.D., Adamson S.J., Pooley S., Robertson R., Henderson C. Consumer and treatment provider perspectives on reducing barriers to opioid substitution treatment and improving treatment attractiveness. Addict. Behav. 2011, 36:636-642. 10.1016/j.addbeh.2011.01.004.
22. Degenhardt L., Larney S., Kimber J., Gisev N., Farrell M., Dobbins T., Weatherburn D.J., Gibson A., Mattick R., Butler T., Burns L. The impact of opioid substitution therapy on mortality post-release from prison. Drug Alcohol Depend. 2015, 146:e260. 10.1016/j.drugalcdep.2014.09.173.
23. Degenhardt L., Larney S., Kimber J., Gisev N., Farrell M., Dobbins T., Weatherburn D.J., Gibson A., Mattick R., Butler T., Burns L. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction 2014, 109:1306-1317. 10.1111/add.12536.
24. Dennis B., Naji L., Bawor M., Bonner A., Varenbut M., Daiter J., Plater C., Pare G., Marsh D.C., Worster A., Desai D., Samaan Z., Thabane L. The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol. Syst. Rev. 2014, 3:105. 10.1186/2046-4053-3-105.
25. EMCDDA, European Monitoring Centre for Drugs and Drug Addiction, 2012. HIV In Injecting Drug Users In The EU/EEA, Following A Reported Increase Of Cases In Greece And Romania. Lisbon, Portugal.
26. EMCDDA, European Monitoring Centre for Drugs and Drug Addiction, 2012. 2012 Annual Report On The State Of The Drugs Problem In Europe. Lisbon, Portugal. 10.2810/32306.
27. EMCDDA, European Monitoring Centre for Drugs and Drug Addiction, 2015. European Drug Report 2015: trends and developments. Lisbon, Portugal. 0.2810/084165.
28. EMCDDA, European Monitoring Centre for Drugs and Drug Addiction, 2015. European Drug Report: trends and developments. Lisbon, Portugal.
29. Fareed A., Vayalapalli S., Casarella J., Drexler K. Effect of buprenorphine dose on treatment outcome. J. Addict. Dis. 2012, 31:8-18. 10.1080/10550887.2011.642758.
30. Farré M., Mas A., Torrens M., Moreno V., Camí J. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend. 2002, 65:283-290.
31. Feelemyer J.P., Jarlais D.C., Des Arasteh K., Phillips B.W., Hagan H. Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: A\an international systematic review. Drug Alcohol Depend. 2014, 134:251-258. 10.1016/j.drugalcdep.2013.10.011.
32. Gerra G., Saenz E., Busse A., Maremmani I., Ciccocioppo R., Zaimovic A., Gerra M.L., Amore M., Manfredini M., Donnini C., Somaini L. Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35:483-489. 10.1016/j.pnpbp.2010.12.002.
33. Gibson A., Degenhardt L., Mattick R.P., Ali R., White J., O'Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction 2008, 103:462-468. 10.1111/j.1360-0443.2007.02090.x.
34. Gibson D.R., Flynn N.M., McCarthy J.J. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 1999, 13:1807-1818.
35. Gjersing L., Bretteville-Jensen A.L. Is opioid substitution treatment beneficial if injecting behaviour continues?. Drug Alcohol Depend. 2013, 133:121-126. 10.1016/j.drugalcdep.2013.05.022.
36. Gowing L., Farrell M.F., Bornemann R., Sullivan L.E., Ali R. Oral substitution treatment for injecting opioid users reduces drug-related behaviours with a high risk of HIV transmission, but has less effect on sex-related risk behaviours. Health (Irvine) 2011.
37. Gowing L., Farrell M.F., Bornemann R., Sullivan L.E., Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst. Rev. 2011, CD004145. pub4. 10.1002/14651858.
38. Green B.N., Johnson C.D., Adams A. Writing narrative literature reviews for peer-reviewed journals: secrets of the trade. J. Chiropr. Med. 2006, 5:101-117. 10.1016/s0899-3467(07) 60142-6.
39. Gunderson E.W., Fiellin D.A. Office-based maintenance treatment of opioid dependence. CNS Drugs 2008, 22:99-111. 10.2165/00023210-200822020-00002.
40. Hedrich D., Alves P., Farrell M., Stöver H., Møller L., Mayet S. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction 2012, 107:501-517. 10.1111/j.1360-0443.2011.03676.x.
41. Hesse M., Pedersen M.U. Easy-access services in low-threshold opiate agonist maintenance. Int. J. Ment. Health Addict. 2007, 6:316-324. 10.1007/s11469-007-9084-6.
42. Humber N., Piper M., Appleby L., Shaw J. Characteristics of and trends in subgroups of prisoner suicides in England and Wales. Psychol. Med. 2011, 41:2275-2285.
43. Johns A. Opiate treatments. Addiction 1994, 89:1551-1558. 10.1111/j.1360-0443.1994.tb03757.x.
44. Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., Bigelow G.E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N. Engl. J. Med 2000, 10.1056/nejm200011023431802.
45. Kleber H.D. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin. Neurosci. 2007, 9:455-470.
46. Kraus M.L., Alford D.P., Kotz M.M., Levounis P., Mandell T.W., Meyer M., Salsitz E.A., Wetterau N., Wyatt S.A. Statement of the American Society of addiction medicine consensus panel on the use of Buprenorphine in office-based treatment of opioid addiction. J. Addict. Med. 2011, 5:254-263. 10.1097/adm.0b013e3182312983.
47. Larance B., Carragher N., Mattick R.P., Lintzeris N., Ali R., Degenhardt L. A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses?. Drug Alcohol Depend. 2014, 142:46-55. 10.1016/j.drugalcdep.2014.05.018.
48. Larney S., Gisev N., Farrell M., Dobbins T., Burns L., Gibson A., Kimber J., Degenhardt L. Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study. Drug Alcohol Depend. 2015, 146:e168. 10.1016/j.drugalcdep.2014.09.373.
49. Larney S., Gisev N., Farrell M., Dobbins T., Burns L., Gibson A., Kimber J., Degenhardt L. Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study. BMJ Open 2014, 4:e004666. 10.1136/bmjopen-2013-004666.
50. Larney S., Grebely J., Falster M., Swart A., Amin J., Degenhardt L., Burns L., Vajdic C.M. Opioid substitution therapy is associated with increased detection of hepatitis C virus infection: a 15-year observational cohort study. Drug Alcohol Depend. 2015, 148:213-216. 10.1016/j.drugalcdep.2014.12.027.
51. Larney S., Toson B., Burns L., Dolan K. Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration. Addiction 2012, 107:372-380. 10.1111/j.1360-0443.2011.03618.x.
52. Lawrinson P., Ali R., Buavirat A., Chiamwongpaet S., Dvoryak S., Habrat B., Jie S., Mardiati R., Mokri A., Moskalewicz J., Newcombe D., Poznyak V., Subata E., Uchtenhagen A., Utami D.S., Vial R., Zhao C. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction 2008, 103:1484-1492. 10.1111/j.1360-0443.2008.02249.x.
53. Levy S., Vaughan B.L., Angulo M., Knight J.R. Buprenorphine replacement therapy for adolescents with opioid dependence: early experience from a children's hospital-based outpatient treatment program. J. Adolesc. Health 2007, 40:477-482. 10.1016/j.jadohealth.2006.11.142.
54. Luce J., Strike C. A Cross-Canada Scan Of Methadone Maintenance Treatment Policy Developments 2011, Canadian Executive Council on Addictions, Toronto.
55. Maher L., White B., Dore G., Lloyd A., Rawlinson W. Opioid substitution treatment protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study. Drug Alcohol Depend 2015, 146:e191. 10.1016/j.drugalcdep.2014.09.435.
56. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev. 2009, 10.1002/14651858.cd002209.pub2.
57. Mauger S., Fraser R., Gill K. Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence. Neuropsychiatr. Dis. Treat. 2014, 10:587-598. 10.2147/NDT.S39692.
58. McLellan A.T., Arndt I.O., Metzger D.S., Woody G.E., O'Brien C.P. The effects of psychosocial services in substance abuse treatment. JAMA 1993, 269:1953-1959.
59. Mofizul Islam M., Topp L., Conigrave K.M., Day C.A. Defining a service for people who use drugs as low-threshold: what should be the criteria?. Int. J. Drug Policy 2013, 24:220-222. 10.1016/j.drugpo.2013.03.005.
60. Murphy S.M., Fishman P.A., McPherson S., Dyck D.G., Roll J.R. Determinants of buprenorphine treatment for opioid dependence. J. Subst. Abuse Treat. 2014, 46:315-319. 10.1016/j.jsat.2013.09.003.
61. Nielsen S., Roxburgh A., Bruno R., Lintzeris N., Jefferson A., Degenhardt L. Changes in non-opioid substitution treatment episodes for pharmaceutical opioids and heroin from 2002 to 2011. Drug Alcohol Depend. 2015, 149:212-219. 10.1016/j.drugalcdep.2015.02.004.
62. Nosyk B., Anglin M.D., Brissette S., Kerr T., Marsh D.C., Schackman B.R., Wood E., Montaner J.S.G. A call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health Aff. (Millwood) 2013, 32:1462-1469. 10.1377/hlthaff.2012.0846.
63. Nosyk B., Guh D.P., Sun H., Oviedo-Joekes E., Brissette S., Marsh D.C., Schechter M.T., Anis A.H. Health related quality of life trajectories of patients in opioid substitution treatment. Drug Alcohol Depend. 2011, 118:259-264. 10.1016/j.drugalcdep.2011.04.003.
64. Nosyk B., Min J.E., Colley G., Lima V., Yip B., Milloy M., Wood E., Montaner J. The causal effect of opioid substitution treatment on highly active antiretroviral treatment adherence. Drug Alcohol Depend. 2015, 146:e53-e54. 10.1016/j.drugalcdep.2014.09.516.
65. Pilling S., Strang J., Gerada C. Psychosocial interventions and opioid detoxification for drug misuse: summary of NICE guidance. BMJ 2007, 335:203-205. 10.1136/bmj.39265.639641.ad.
66. Polonsky M., Azbel L., Wickersham J.A., Taxman F.S., Grishaev E., Dvoryak S., Altice F.L. Challenges to implementing opioid substitution therapy in Ukrainian prisons: personnel attitudes toward addiction, treatment, and people with HIV/AIDS. Drug Alcohol Depend. 2015, 148:47-55. 10.1016/j.drugalcdep.2014.12.008.
67. Prodromou M., Kyritsi E., Samartzis L. Dual diagnosis affects prognosis in patients with drug dependence in integrative care setting. Health Sci. J. 2014, 8:216-228.
68. Riksheim M., Gossop M., Clausen T. From methadone to buprenorphine: changes during a 10 year period within a national opioid maintenance treatment programme. J. Subst. Abuse Treat. 2014, 46:291-294. 10.1016/j.jsat.2013.10.006.
69. Rivlin A., Ferris R., Marzano L., Fazel S., Hawton K. A typology of male prisoners making near-lethal suicide attempts. Crisis 2013, 34:335-347. 10.1027/0227-5910/a000205.
70. Roux P., Carrieri M.P., Cohen J., Ravaux I., Poizot-Martin I., Dellamonica P., Spire B. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin. Infect. Dis. 2009, 49:1433-1440. 10.1086/630209.
71. Shepherd A., Perrella B., Hattingh H. The impact of dispensing fees on compliance with opioid substitution therapy: a mixed methods study. Subst. Abuse Treat. Prev. Policy 2014, 9:32. 10.1186/1747-597x-9-32.
72. Stöver H. Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians. Eur. Addict. Res. 2011, 17:44-54. 10.1159/000320576.
73. Stöver H., Michels I.I. Drug use and opioid substitution treatment for prisoners. Harm Reduct. J. 2010, 7:17. 10.1186/1477-7517-7-17.
74. Torjesen I. Heroin substitute treatment should not be time limited, says report commissioned by government. BMJ 2014, 349:g6715. 10.1136/bmj.g6715.
75. Torrens M., Castillo C., Pérez-Solá V. Retention in a low-threshold methadone maintenance program. Drug Alcohol Depend 1996, 41:55-59.
76. Treloar C., Rance J., Grebely J., Dore G.J. Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia. Drug Alcohol Depend. 2013, 133:529-534. 10.1016/j.drugalcdep.2013.07.023.
77. Waal H. Merits and problems in high-threshold methadone maintenance treatment. Evaluation of medication-assisted rehabilitation in Norway 1998-2004. Eur. Addict. Res. 2007, 13:66-73. 10.1159/000097935.
78. Weber R., Huber M., Rickenbach M., Furrer H., Elzi L., Hirschel B., Cavassini M., Bernasconi E., Schmid P., Ledergerber B. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV Med. 2009, 10:407-416. 10.1111/j.1468-1293.2009.00701.x.
79. WHO, 2004. WHO|WHO/UNODC/UNAIDS position paper on substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention. World Health Organization Geneva.
80. WHO Department of Mental Health and Substance Abuse, 2009. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. WHO, Geneva.
81. Wikner B.N., Öhman I., Seldén T., Druid H., Brandt L., Kieler H. Opioid-related mortality and filled prescriptions for buprenorphine and methadone. Drug Alcohol Rev. 2014, 33:491-498. 10.1111/dar.12143.
82. Woody G., Bruce D., Korthuis P.T., Chhatre S., Hillhouse M., Jacobs P., Sorensen J., Saxon A.J., Metzger D., Ling W. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J. Acquired Immune Deficiency Syndr. 2014, 66:288-293. 10.1097/QAI.0000000000000165.
83. Wood G.E. You cannot be in recovery if you are on medication: a concept worth retiring. Subst. Use Misuse 2015, 50:1020-1023. 10.3109/10826084.2015.1007696.
84. Wright N.M.J., Sheard L., Adams C.E., Rushforth B.J., Harrison W., Bound N., Hart R., Tompkins C.N.E. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trialarison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial. Br. J. Gen. Pract. 2011, 61:772-780. 10.3399/bjgp11x613106.